Topical 5% Niacinamide for Skin Cancer Prevention in Organ Transplant Recipients
Official title: A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients
Run by University of Pittsburgh · NCT07286318 · Data updated 2026-11-12
This trial tests whether applying a 5% niacinamide cream daily, in addition to sunscreen, can reduce actinic keratoses and new skin cancers in adults who have had an organ transplant.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | University of Pittsburgh Academic / other |
| Drugs / interventions | radiation |
| Locations | 2 sites (Pittsburgh, Pennsylvania and 1 other locations) |
| Status | Recruiting |
| Started | May 1, 2026 |
| Main results expected | May 28, 2027 |
| Study ends | June 30, 2027 |
| Registry record updated | June 5, 2026 |
| Trial ID | NCT07286318 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) who have had a solid organ transplant and have experienced at least 5 actinic keratoses in the past year or a prior history of skin cancer.
✕Probably not a fit
Patients without a history of multiple actinic keratoses or skin cancer, or those unable to use sunscreen as required, may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
In this early Phase 1 trial, organ transplant recipients with a high risk of skin cancer will use a topical 5% niacinamide cream and sunscreen daily to see if it lowers the number of actinic keratoses over 6 and 12 months and reduces new keratinocyte cancers compared with sunscreen alone. The study also monitors safety, tolerability, and patient experience with the topical product. Participants must continue using SPF30 sunscreen and meet specific eligibility criteria related to transplant history and skin condition. The trial is conducted at two dermatology clinics in Pittsburgh and is led by Marissa Lobl. The findings could inform preventive skin care strategies for immunosuppressed patients.
Why it matters
Potential benefit: If successful, the approach could reduce skin cancer risk and precancerous lesions in organ transplant recipients.
How similar studies have gone: Prior data suggest niacinamide may help protect skin, but results in this specific high-risk population are exploratory and this approach is relatively novel in organ transplant recipients.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Age ≥18 History of solid organ transplantation At least 5 AKs in the past year or prior history of skin cancer Participants are willing to continue using SPF30 sunscreen from their own supply Exclusion Criteria: Known allergy to niacinamide or sunscreen components Eczema or other skin conditions for which niacinamide is contraindicated
Where it's running
-
UPMC Falk Dermatology
Pittsburgh, Pennsylvania, United States Recruiting -
UPMC St Margarets Dermatology
Pittsburgh, Pennsylvania, United States Recruiting
Study contacts
- Study coordinator: Marissa Lobl, Resident Physician, Principal Investigator, MD, PhD
- Email: loblm@Upmc.edu
- Phone: 2244566009
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Injecting flu vaccine into skin cancer tumors before surgery
This study is testing whether injecting the flu vaccine into skin cancer tumors before surgery can help boost the body's immune response against the cancer in people with cutaneous squamous cell carcinoma.
-
Mobile sun protection support to help young adults stay safe in the sun
This project tests a mobile health program to see if reminders, education, planning tools, and real-time sun exposure information can help young adults protect their skin from excessive sun exposure.
-
Multimodal Laser Treatment for Photodamaged Facial Skin
A randomized split-face study tests a combination of three lasers and light therapy to improve sun-damaged facial skin and potentially help prevent skin cancer in adults with actinic keratosis.
-
Seeing if the first lymph node helps detect skin cancer spread earlier
They are testing whether checking the sentinel lymph node early can help see if high-risk skin squamous cell cancer has started to spread.
-
Pharmacokinetic test of reformulated Levulan Kerastick for actinic keratosis on forearms or face
This study tests how the reformulated Levulan Kerastick behaves in the body when used on actinic keratosis lesions on the arms or face, followed by blue-light treatment.
-
Tirbanibulin in adults with facial actinic keratosis: seeing if it improves appearance and skin feel
This study checks whether tirbanibulin used for facial actinic keratosis helps improve how the skin looks and feels over 57 days in adults already using the medicine.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.